CEACAM5/CEACAM6 (NEO-201 Biosimilar) Recombinant Monoclonal Antibody

This recombinant monoclonal antibody is a research-grade biosimilar of NEO-201, targeting tumor-associated variants of CEACAM5 (carcinoembryonic antigen, also known as CEA or CD66e) and CEACAM6 (also known as NCA-90 or CD66c). CEACAM5 and CEACAM6 are GPI-anchored cell surface glycoproteins belonging to the immunoglobulin superfamily. While expressed at low levels in normal epithelial tissues, these proteins are significantly overexpressed in multiple carcinomas, including colorectal, pancreatic, breast, lung, and ovarian cancers. CEACAM6 typically exhibits higher expression than CEACAM5 in tumors and promotes cancer progression through Src-FAK signaling, inhibition of anoikis, enhanced cell adhesion, migration, and metastasis. NEO-201 is a humanized IgG1 antibody that uniquely recognizes tumor-specific glycosylation variants of CEACAM5 and CEACAM6, distinguishing malignant cells from normal tissues expressing these proteins. This selective binding enables dual mechanisms of action: inducing antibody-dependent cellular cytotoxicity and blocking the inhibitory CEACAM5-CEACAM1 interaction on NK cells to restore antitumor immunity. This biosimilar provides researchers with a valuable tool for investigating CEACAM-mediated tumor biology, studying immune checkpoint pathways, and exploring therapeutic strategies targeting aberrant glycosylation patterns in cancer.